Cargando…

The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025

BACKGROUND: Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade...

Descripción completa

Detalles Bibliográficos
Autores principales: Golpour, Monireh, Vatanpour, Pouya, Amini, Mina, Saeedi, Majid, Hafezi, Nasim, Rafiei, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026318/
https://www.ncbi.nlm.nih.gov/pubmed/33860229
http://dx.doi.org/10.1155/2021/5569590
_version_ 1783675651405905920
author Golpour, Monireh
Vatanpour, Pouya
Amini, Mina
Saeedi, Majid
Hafezi, Nasim
Rafiei, Alireza
author_facet Golpour, Monireh
Vatanpour, Pouya
Amini, Mina
Saeedi, Majid
Hafezi, Nasim
Rafiei, Alireza
author_sort Golpour, Monireh
collection PubMed
description BACKGROUND: Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. OBJECTIVE: Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. METHODS: Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025. RESULTS: The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future. CONCLUSION: Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly.
format Online
Article
Text
id pubmed-8026318
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-80263182021-04-14 The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025 Golpour, Monireh Vatanpour, Pouya Amini, Mina Saeedi, Majid Hafezi, Nasim Rafiei, Alireza Adv Pharmacol Pharm Sci Research Article BACKGROUND: Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade. OBJECTIVE: Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data. METHODS: Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025. RESULTS: The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future. CONCLUSION: Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly. Hindawi 2021-03-30 /pmc/articles/PMC8026318/ /pubmed/33860229 http://dx.doi.org/10.1155/2021/5569590 Text en Copyright © 2021 Monireh Golpour et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Golpour, Monireh
Vatanpour, Pouya
Amini, Mina
Saeedi, Majid
Hafezi, Nasim
Rafiei, Alireza
The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025
title The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025
title_full The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025
title_fullStr The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025
title_full_unstemmed The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025
title_short The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025
title_sort perspective of therapeutic antibody marketing in iran: trend and estimation by 2025
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026318/
https://www.ncbi.nlm.nih.gov/pubmed/33860229
http://dx.doi.org/10.1155/2021/5569590
work_keys_str_mv AT golpourmonireh theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT vatanpourpouya theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT aminimina theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT saeedimajid theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT hafezinasim theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT rafieialireza theperspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT golpourmonireh perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT vatanpourpouya perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT aminimina perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT saeedimajid perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT hafezinasim perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025
AT rafieialireza perspectiveoftherapeuticantibodymarketinginirantrendandestimationby2025